IGF-1 LR3 SPECIFICATIONS
Molecular Formula: C400H625N111O115S9
Molecular Weight: 9117.60 g/mol
Sequence: MFPAMPLSSL FVNGPRTLCG AELVDALQFV CGDRGFYFNK PTGYGSSSRR APQTGIVDEC CFRSCDLRRL EMYCAPLKPA KSA
CAS Number: 946870-92-4
What is IGF-1 LR3 Peptide?
IGF-1 LR3 is an altered variant of insulin-like growth factor-1; the complete name of the peptide is insulin-like growth factor-1 long arginine 3. All IGF-1 derivatives play important roles in cell proliferation, cell division, and cell-to-cell communication. Despite showing physiological effects similar to the parent protein, IGF-1 LR3 does not interact with IGF binding proteins as strongly as IGF-1. Hence, it stays in the bloodstream for longer durations (about 120 times longer) as compared to native IGF-1. The structural modifications in IGF1-LR3 have contributed to its increased half-life in the blood. The peptide is created by the inclusion of 13 amino acids to the N-terminus of native IGF-1 and by replacing the glutamic acid at position 3 to arginine.
Like IGF-1, IGF1-LR3 acts as a potent stimulus for cell division and proliferation. It primarily affects connective tissues of the muscle and bone and promotes cell division in the liver, kidney, skin, lung, nerve, and blood tissues. IGF-1 is best considered to be a maturation hormone because it influences cell proliferation, differentiation, and maturation, thereby helping them to carry out their specialized functions.
The longer life span of IGF1-LR3 in the blood makes it a much more potent molecule as compared to IGF-1. A single dose of IGF1-LR3 provides about thrice as much cellular activation compared to a similar dose of IGF-1. It is important to remember that IGF-1 LR3 peptide and every IGF-1 derivative do not mediate cellular enlargement (hypertrophy), and instead may participate in cell division and proliferation (hyperplasia). For instance, in the case of muscle, IGF-1 LR3 does not cause enlargement of muscle cells but increases the total number of muscle cells.
Impairment of Myostatin
Myostatin (also known as growth differentiation factor 8) is a muscle protein that primarily suppresses the growth and differentiation of muscle cells. Myostatin is, thus crucial in protection from unregulated hypertrophy and proper healing post-injury. However, some situations that demand inhibition of myosin. Blocking of myosin can be helpful in conditions like Duchenne muscular dystrophy (DMD) or in people who suffer from loss of muscle due to prolonged immobility. In such cases, blocking the natural enzyme could help slow down muscle breakdown, maintain strength, and avoid morbidity.
Studies conducted in mouse models of DMD have shown that IGF-1 LR3 and other IGF-1 derivatives can overcome the adverse effects of myostatin to protect muscle cells and prevent apoptosis. IGF1-LR3, due to its long stability, is highly effective in counteracting myostatin and functions by activating MyoD, a muscle protein that is normally triggered by exercise (e.g., weight lifting) or tissue damage and mediates muscle hypertrophy.
Fat Metabolism and Diabetes
IGF-1 LR3 indirectly boosts fat burning by associating with the IGF-1R receptor and the insulin receptor. These interactions improve glucose uptake from the blood by muscle, nerve, and liver cells. Thus, there is an overall reduction in blood sugar levels, which then triggers adipose tissue as well as the liver to initiate catabolism of glycogen and triglycerides. Overall, this leads to a decrease in adipose tissue and net energy consumption (i.e. net catabolism).
Given its role in controlling blood sugar levels, IGF1-LR3 reduces insulin levels and the need for exogenous insulin in diabetes. In a majority of the patients, this brings about a 10% reduction in insulin requirements to maintain the same blood sugar levels. IGF1-LR3 thus helps understand insulin regulation in patients with decreased insulin sensitivity. It also highlights possible ways to prevent type 2 diabetes.
IGF-1 LR3 Peptide – Longevity Research
IGF-1 LR3 promotes tissue repair and upkeep of the body, making it a protective molecule against cellular damage and the effects of aging. Research in cows and pigs indicates that IGF1-LR3 administration can overcome the effects of aging, prolong life and reduce disability. Ongoing research in mice has focused on the potential of IGF1-LR3 in preventing the progression of a wide range of conditions such as muscle atrophy, dementia, and kidney disease.
IGF-1 LR3 Peptide – Glucocorticoid Signaling
Glucocorticoids, produced essentially from the adrenal glands, also act as important clinical drugs which help to control pain and decrease inflammation in autoimmune diseases, cancer, and neurological injuries, to name a few. However, glucocorticoids have numerous undesirable side effects, such as muscle wasting, fat gain, and deterioration of bone density. Thus, IGF1-LR3 is being explored as an option to reduce the side effects of glucocorticoids and thereby mediate a more effective therapy. Studies have shown minimal to moderate side effects, low oral bioavailability, and excellent subcutaneous bioavailability in mice.
Per kg dosage in mice does not scale up to the dosage which can be required for humans.